Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Harmony Biosciences Holdings, Inc. HRMY

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$868.5M
▲ 21.5% YoY
$158.7M
▲ 9.1% YoY
$347.9M
▲ 59.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Harmony Biosciences Holdings, Inc. sells WAKIX (pitolisant) to a limited number of specialty distributors, which in turn distribute it to patients. Its lead product, WAKIX (pitolisant), enhances histamine signaling in the brain by binding to H3 receptors. Its corporate headquarters are located at 630 W. Germantown Pike, Plymouth Meeting, Pennsylvania. Net product revenue from sales of WAKIX was $868.5 million for the year ended December 31, 2025. Caremark LLC accounted for 38% of gross product revenue for the year ended December 31, 2025. Its product portfolio spans sleep/wake, rare epilepsy, and neurobehavioral areas of focus. In July 2017, it entered into a license agreement with Bioprojet Société Civile de Recherche under which it acquired the exclusive right to commercialize pitolisant.

Written from the business description in Harmony Biosciences Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 868.5M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 868.5 · Net income 158.7
400M800M-100M-200M
201920222025
Compound annual growth
+25.6%
+40.3%
−4.4%
−3.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +40.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

18 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 24.0% · Net 18.3%
-1000%-2000%
201920222025
ROE
FY2025 · ROE 20.8%
20%40%60%
201920222025
Three returns, three denominators.

Each USD of equity produced 21 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 347.9
150M300M-30M-60M
201920222025
Net buybacks $M Dividends $M
FY2023 · Dividends · · Net buybacks 94.9
40M80M
20202023

Total assetsUSD 1.3B
EquityUSD 870.2M
CashUSD 752.5M
Gross debtUSD 163.7M
Net debtUSD -588.8M
Current ratio3.60×

The company holds more cash than debt.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HRMY, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.90.70.60.40.30.20.0
Operating income $B0.20.20.20.10.10.0−0.1
EBITDA $B◌0.20.20.10.10.0−0.1
Income tax $B0.10.00.0−0.10.0◌◌
Net income $B0.20.10.10.20.0−0.0−0.2
Free cash flow $B0.30.20.20.10.1−0.0−0.1
EPS, diluted $2.712.512.132.970.58−2.48−24.07
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %20.825.829.661.624.4——
Shares out B0.060.060.060.060.060.060.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image